4D Molecular Therapeutics, Inc. Comprehensive Income
4D Molecular Therapeutics, Inc. (FDMT) reported Comprehensive Income of -$73.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$73.20M.
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$69.67M.
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $19.45M.
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$56.54M.
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$139.61M.
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$160.66M.
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$99.63M.
- 4D Molecular Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$108.27M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$73.20M 10-Q · filed 2026-08-13 | -$142.87M 10-Q · filed 2026-08-13 | -$123.42M derived: sum of 3 quarters · filed 2026-08-13 | -$179.96M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$69.67M 10-Q · filed 2026-05-07 | -$50.21M derived: sum of 2 quarters · filed 2026-05-07 | -$106.76M derived: sum of 3 quarters · filed 2026-05-07 | -$161.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$37.09M derived: sum of 2 quarters · filed 2026-03-18 | -$91.74M derived: sum of 3 quarters · filed 2026-08-13 | -$139.61M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$56.54M 10-Q · filed 2025-11-10 | -$111.19M derived: sum of 2 quarters · filed 2026-08-13 | -$159.06M 10-Q · filed 2025-11-10 | -$209.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$54.65M 10-Q · filed 2026-08-13 | -$102.52M 10-Q · filed 2026-08-13 | -$153.04M derived: sum of 3 quarters · filed 2026-08-13 | -$195.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$47.87M 10-Q · filed 2026-05-07 | -$98.39M derived: sum of 2 quarters · filed 2026-05-07 | -$140.86M derived: sum of 3 quarters · filed 2026-05-07 | -$176.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$50.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$92.99M derived: sum of 2 quarters · filed 2026-03-18 | -$128.13M derived: sum of 3 quarters · filed 2026-03-18 | -$160.66M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$42.47M 10-Q · filed 2025-11-10 | -$77.61M derived: sum of 2 quarters · filed 2025-11-10 | -$110.13M 10-Q · filed 2025-11-10 | -$142.94M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$35.14M 10-Q · filed 2025-08-11 | -$67.66M 10-Q · filed 2025-08-11 | -$100.46M derived: sum of 3 quarters · filed 2025-08-11 | -$110.53M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$32.53M 10-Q · filed 2025-05-08 | -$65.33M derived: sum of 2 quarters · filed 2025-05-08 | -$75.39M derived: sum of 3 quarters · filed 2025-05-08 | -$104.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$32.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$42.87M derived: sum of 2 quarters · filed 2025-02-28 | -$71.87M derived: sum of 3 quarters · filed 2025-02-28 | -$99.63M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$10.07M 10-Q · filed 2024-11-13 | -$39.07M derived: sum of 2 quarters · filed 2024-11-13 | -$66.82M 10-Q · filed 2024-11-13 | -$93.55M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$29.00M 10-Q · filed 2024-08-08 | -$56.76M 10-Q · filed 2024-08-08 | -$83.48M derived: sum of 3 quarters · filed 2024-08-08 | -$109.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$27.76M 10-Q · filed 2024-05-09 | -$54.48M derived: sum of 2 quarters · filed 2024-05-09 | -$80.19M derived: sum of 3 quarters · filed 2024-05-09 | -$108.69M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$26.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$52.44M derived: sum of 2 quarters · filed 2024-02-29 | -$80.93M derived: sum of 3 quarters · filed 2024-02-29 | -$108.27M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$25.71M 10-Q · filed 2023-11-09 | -$54.21M derived: sum of 2 quarters · filed 2023-11-09 | -$81.54M 10-Q · filed 2023-11-09 | -$106.85M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$28.49M 10-Q · filed 2023-08-09 | -$55.83M 10-Q · filed 2023-08-09 | -$81.14M derived: sum of 3 quarters · filed 2023-08-09 | -$103.57M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$27.34M 10-Q · filed 2023-05-11 | -$52.65M derived: sum of 2 quarters · filed 2023-05-11 | -$75.08M derived: sum of 3 quarters · filed 2023-05-11 | -$82.67M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$25.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$47.74M derived: sum of 2 quarters · filed 2023-03-15 | -$55.33M derived: sum of 3 quarters · filed 2023-03-15 | -$71.74M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$22.43M 10-Q · filed 2022-11-08 | -$30.02M derived: sum of 2 quarters · filed 2022-11-08 | -$46.43M 10-Q · filed 2022-11-08 | -$66.98M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$7.59M 10-Q · filed 2022-08-11 | -$24.00M 10-Q · filed 2022-08-11 | -$44.54M derived: sum of 3 quarters · filed 2022-08-11 | -$52.38M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$16.41M 10-Q · filed 2022-05-12 | -$36.95M derived: sum of 2 quarters · filed 2022-05-12 | -$44.79M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$20.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$28.38M derived: sum of 2 quarters · filed 2022-03-28 | -$56.69M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$7.83M 10-Q · filed 2021-11-10 | -$36.15M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |